Image
Managing Alzheimer’s Disease Where Are We Now and Where Are We Going?

Marwan N. Sabbagh, MD, FAAN

This activity is jointly provided by Global Education Group and Integritas Communications.

 

This activity is supported by an educational grant from Biogen MA, Inc.

Faculty

Marwan N. Sabbagh, MD, FAAN
Director, Cleveland Clinic Lou Ruvo Center for Brain Health
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine
Clinical Professor, Department of Neurology
University of Nevada, Las Vegas
Las Vegas, Nevada

Target Audience

The educational design of this activity addresses the needs of physicians, nurse practitioners, and other allied health care professionals who treat patients with Alzheimer's disease (AD).

Educational Objective

After completing this activity, the participant should be better able to:

  • Assess patients with mild cognitive impairment and AD using cognitive scales, biomarker imaging, clinical examination, and patient/caregiver interviews
  • Describe challenges, results, and future directions with emerging therapies for AD

Statement of Need

AD is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. It affects approximately 5.8 million Americans.1 Early diagnosis of AD is shaped by patient and caregiver interviews, cognitive testing, and standard imaging. Once diagnosed, patients and their caregivers face numerous challenges, all of which require longitudinal treatment, ongoing monitoring, and an intensive commitment to patient/caregiver education and engagement. Symptomatic therapies are available for patients with AD. The range of neurotransmitter-focused medications, however, is limited.1 There is a plethora of evidence suggesting active management can improve quality of life if performed correctly. This requires collaborative care, which should include patients and caregivers, education, comorbidity management, social interaction, and appropriate use of available treatments.1 Amyloid- and tau-targeted therapies are in clinical trials, and, if approved, these therapies would change the landscape of AD management.2,3 It is critical for clinicians to be well educated about current management strategies, collaborative care, patient education, and emerging therapies and patient selection. This self-assessment activity presents real-life case scenarios for clinicians to gauge and learn about optimal practice strategies for diagnosis and management of AD, as well as how emerging therapies may eventually be employed.

References

  1. Alzheimer’s Association. 2021 Alzheimer’s Disease Facts and Figures.
    https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. Accessed April 6, 2021.
  2. Budd Haeberlein S, et al. Clinical Trials on Alzheimer’s Disease; December 4-7, 2019; San Diego, CA.
  3. Congdon EE, Sigurdsson EM. Nat Rev Neurol. 2018;14(7):399-415.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour (which includes 0.1 hour of pharmacology).

Term of Offering

This activity was released on April 21, 2021 and is valid for 1 year. Requests for credit must be made no later than April 21, 2022.

Global Contact Information

For information about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 70% or better on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Marwan N. Sabbagh, MD, FAAN Consultant/Independent Contractor: Acadia Pharmaceuticals, Inc., Alzheon Inc., Biogen Inc., Cortexyme, Inc., Danone S.A., Neurotrope Biosciences, Regeneron Pharmaceuticals, Inc., Roche-Genentech, Inc., State 2 Innovations; Speakers Bureau: Health and Wellness Partners, LLC, Knapp Healthcare Communications, LLC; Stock Shareholder: Athira Pharma, Brain Health Inc, NeuroReserve Inc., NeuroTau, Inc., Optimal Cognitive Health Company, LLC, uMETHOD Health, Inc., Versanum Inc.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Gena Dolson, MS, Stacey JP Ullman, MHS

System Requirements

PC
Microsoft Windows 2000 SE or above.
Internet Explorer (v5.5 or greater), Chrome, or Firefox

MAC
MAC OS 10.2.8
Safari
Internet Explorer is not supported on the Macintosh.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

credit amount 0.25

credit type CME/AANP

release 04/22/2021

expiration 04/22/2022